PAHC Phibro Animal Health Corporation
PAHC Phibro Animal Health Corporation
Healthcare · Drug Manufacturers - Specialty & Generic
Desk view
Market read
POC $40.68 · VWAP $41.05 · -15.6% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 related perspective
PAHC Price Structure
Loading timeframes…
Peers
Every watchlist PAHC belongs to, members best 30-day change first — PAHC highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@livestock-disease
Against street estimates
How PAHC's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about PAHC from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 35 days ago · Jul 14
- Phibro Animal Health Corporation (PAHC) Receives Consensus Rating of 'Hold' from Analysts
- Phibro names new CEO with performance RSU package | PAHC 8-K Filing
- Should You Continue to Hold PAHC Stock in Your Portfolio?
- PAHC Stock: What's Driving Phibro's Animal Health Growth
- Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
PAHC research tape
2 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.